Program
Encapsulated Rapamycin
Also written as “eRapa (encapsulated rapamycin)” and “Encapsulated Rapamycin (eRapa)”.
Its studies are mostly in Adenomatous Polyposis Coli · Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rapamycin | 21 open or running | phase 3since Apr 10, 2025 | Jan 12, 2020 | Jul 2030phase 3 · NCT06950385 |
| Rapamycin Holdings, Inc. dba Emtora Biosciences | 10 open or running | phase 1since Jun 12, 2018 | Jun 12, 2018 | none ahead |
Also a collaborator on its studies: cancer-insight-llc and biodexa-pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2018First study: phase 1 study in Prostatic NeoplasmsNew to Rapamycin Holdings, Inc. dba Emtora BiosciencesRapamycin Holdings, Inc. dba Emtora Biosciences · NCT03618355 · 15 enrolled · United States
- Jan 12, 2020Rapamycin's first study: phase 2 study in Adenomatous Polyposis ColiNew to RapamycinRapamycin · NCT04230499 · 30 enrolled · United States
- Apr 10, 2025Phase 3 study in Adenomatous Polyposis ColiRapamycin · NCT06950385 · 168 planned · United States, Denmark, Germany and more
Ahead
- Jul 2030Primary completion: phase 3 study in Adenomatous Polyposis ColiRapamycin · NCT06950385
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06950385Adenomatous Polyposis Coli · United States, Denmark, Germany and more | 3 | Recruiting | Rapamycin | Jul 2030 | 168 |
| NCT04230499Adenomatous Polyposis Coli · United States | 2 | Completed | Rapamycin | Dec 11, 2024 | 30 |
| NCT03618355Prostatic Neoplasms · United States | 1 | Completed | Rapamycin Holdings, Inc. dba Emtora Biosciences | Dec 2, 2019 | 15 |
How it is read
Names in the registry
- “eRapa (encapsulated rapamycin)”, 2 entries
- “Encapsulated Rapamycin (eRapa)”, 1 entry
Conditions, from the studies’ own filings
- Adenomatous Polyposis Coli, 2 studies
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.